Title
Whole-Genome Enrichment and Sequencing of Chlamydia trachomatis Directly from Patient Clinical Vaginal and Rectal Swabs.

Permalink
https://escholarship.org/uc/item/9961k9sf

Journal
mSphere, 6(2)

ISSN
2379-5042

Authors
Bowden, Katherine E
Joseph, Sandeep J
Cartee, John C
et al.

Publication Date
2021-03-03

DOI
10.1128/msphere.01302-20

Peer reviewed
Whole-Genome Enrichment and Sequencing of *Chlamydia trachomatis* Directly from Patient Clinical Vaginal and Rectal Swabs

Katherine E. Bowden,* Sandeep J. Joseph,* John C. Cartee,* Noa Ziklo,* Damien Danavall,* Brian H. Raphael,* Timothy D. Read,* Deborah Dean*  

*Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA  
†Emory University School of Medicine, Atlanta, Georgia, USA  
‡University of California San Francisco School of Medicine, San Francisco, California, USA  
§University of California San Francisco Benioff Children’s Hospital Oakland Research Institute, Oakland, California, USA

**ABSTRACT** *Chlamydia trachomatis*, an obligately intracellular bacterium, is the most prevalent cause of bacterial sexually transmitted infections (STIs) worldwide. Numbers of U.S. infections of the urogenital tract and rectum have increased annually. Because *C. trachomatis* is not easily cultured, comparative genomic studies are limited, restricting our understanding of strain diversity and emergence among populations globally. While Agilent SureSelectXT target enrichment RNA bait libraries have been developed for whole-genome enrichment and sequencing of *C. trachomatis* directly from clinical urine, vaginal, conjunctival, and rectal samples, public access to these libraries is not available. We therefore designed an RNA bait library (34,795 120-mer probes based on 85 genomes, versus 33,619 probes using 74 genomes in a previous one) to augment organism sequencing from clinical samples that can be shared with the scientific community. We describe the library and limit of detection for genome copy input, and we present results of 100% efficiency and high-resolution determination of recombination and identical genomes within vaginal-rectal specimen pairs in women. This workflow provides a robust approach for discerning genomic diversity and advancing our understanding of *C. trachomatis* STIs across sample types, geographic populations, sexual networks, and outbreaks associated with proctitis/proctocolitis among women and men who have sex with men.

**IMPORTANCE** *Chlamydia trachomatis* is an obligate intracellular bacterium that is not easily cultured, which limits our understanding of urogenital and rectal *C. trachomatis* transmission and impact on morbidity. To provide a publicly available workflow for whole-genome target enrichment and sequencing of *C. trachomatis* directly from clinical urine, vaginal, conjunctival, and rectal specimens, we developed and reported on an RNA bait library to enrich the organism from clinical samples for sequencing. We demonstrate an increased efficiency in the percentage of reads mapping to *C. trachomatis* and identified recombinant and identical *C. trachomatis* genomes in paired vaginal-rectal samples from women. Our workflow provides a robust genomic epidemiologic approach to advance our understanding of *C. trachomatis* strains causing ocular, urogenital, and rectal infections and to explore geo-sexual networks, outbreaks of colorectal infections among women and men who have sex with men, and the role of these strains in morbidity.

**KEYWORDS** *Chlamydia trachomatis*, SNPs, recombination, whole-genome enrichment

---

*Chlamydia trachomatis* is the most common cause of bacterial sexually transmitted infections (STIs) worldwide and the most notifiable disease in the United States (1, 2).
Although *C. trachomatis* infection can present with conjunctivitis, pharyngitis, urethritis, vaginal discharge, proctitis, or inguinal syndrome, most infections are asymptomatic, which can lead to reproductive morbidity in women and proctitis or proctocolitis in men who go untreated (2).

*C. trachomatis* strains are classified by genotype based on the outer membrane protein gene (*ompA*), which encodes the major outer membrane protein (MOMP) and is typically linked to clinical presentation (3). Genotypes are grouped according to disease association: ocular disease (A to C and Ba), urogenital and anorectal disease (D to K, Da, Ga, Ia, and Ja), and lymphogranuloma venereum (LGV) (L1, L2b, L2c, and L2c) (2, 4–7). Several studies have reported that the prevalence of these genotypes differs by anatomical site and sexual network. Genotypes D and G are more commonly detected in the anorectal tract and, along with genotype J, are prevalent in women and men who have sex with men (MSM) (8–15). Genotypes D, E, and F are found in the majority of urogenital infections and are common among heterosexuals (8, 16). LGV genotypes are prevalent in MSM with and without HIV and are associated with an anorectal infection and the inguinal syndrome (17–21).

A 2016 meta-analysis of extragenital *C. trachomatis* and *Neisseria gonorrhoeae* infections in women, MSM, and men who have sex only with women (MSW) demonstrated median prevalences of 8.7%, 8.9%, and 7.7%, respectively, for rectal *C. trachomatis*, with infection often being asymptomatic (22). Further, a number of studies have shown that rectal infections outnumber those in the urogenital tract of women and are on the increase among MSM (23–28). Although common, rectal *C. trachomatis* transmission and its impact on morbidity are not well understood, likely due to the lack of routine screening of populations other than MSM (1, 22, 29). In May 2019, the FDA cleared two diagnostic tests, the Aptima Combo 2 assay (Hologic, Inc.) and the Xpert CT/NG (Cepheid), for use with extragenital specimens in the detection of *C. trachomatis* and *N. gonorrhoeae*. This recent diagnostic advancement will improve screening and surveillance capacity while offering an opportunity to better understand transmission of rectal *C. trachomatis* and its role in morbidity.

Transmission and molecular epidemiologic studies of *C. trachomatis* rely on *ompA* genotyping, multilocus sequence typing (MLST), and multilocus variable-number tandem-repeat analysis (MLVA) (10, 30–39). Unfortunately, these techniques are challenging and laborious when performed on clinical specimens and, except for *ompA* genotyping, often require tissue culture to generate sufficient DNA. Further, due to low genetic resolution, these methods fail to demonstrate precise inter- and intrastrain recombination events across the genome that contribute to strain diversity (40–44). Recombination has been important in creating emerging strains of *C. trachomatis*, such as L2b, among MSM in many countries of the world and recombinant strains L2/D (termed L2c) and L2b/D-Da in the United States and Portugal, respectively (28, 40–47).

Enrichment of the low copy number of *C. trachomatis* in clinical specimens presents the greatest challenge for culture-independent genome sequencing (48). Initially, this method employed immunomagnetic separation (IMS) for enrichment, followed by genome amplification using multiple displacement amplification (MDA), but the demonstrated success rate (15 to 30%) was low across clinical specimens (49–51). Other methods currently in use include depletion-enrichment, cell sorting-MDA, and multiplexed microdroplet PCR (48). In 2014, Christiansen et al. sequenced *C. trachomatis* from urine and vaginal swabs with an 80% (8/10) success rate (≥95 to 100% coverage of the respective reference genome) using custom RNA baits to enrich for *C. trachomatis* during library preparation (52). The same RNA bait library was subsequently used for conjunctival samples with a 60% (12/20) success rate and similar genome coverage. More recently, another Agilent custom RNA bait library was developed for *C. trachomatis* enrichment from rectal samples (47). This RNA bait method has therefore been used to understand genomic diversity in circulating *C. trachomatis* ocular, urogenital, and LGV lineages from clinical specimens but with varying success (47, 53–56).

In an effort to make direct sequencing of all *C. trachomatis* strains causing clinical
infections more efficient and publicly available, we designed an RNA bait library based on 85 C. trachomatis complete genomes with 34,795 120-mer probes, compared to 74 genomes with 33,619 120-mer probes as for previous bait libraries (48, 52) and optimized the experimental protocol. We used paired vaginal and rectal specimens from four women as a novel comparator but also because the latter sample types have become more clinically relevant due to increased numbers of these infections among heterosexual women (23–28). The new system will increase our ability to sequence C. trachomatis genomes of current circulating strains causing ocular, urogenital, and rectal infections in diverse populations, providing a more robust data set to understand current sexual networks and transmission within and among anatomic sites. From these data, we will be able to differentiate clusters and sporadic cases during outbreaks and potentially identify novel markers for typing C. trachomatis, in addition to exploring the role of these strains in ocular, genital, and colorectal morbidity.

RESULTS

Limit of detection. The limit of detection (LOD) was determined using various genomic copy numbers of a C. trachomatis ompA genotype D strain mapped to the D reference strain. Genomic libraries were prepared, enriched for C. trachomatis, and sequenced from spiked serial dilutions of genomic DNA (gDNA) bulked with human DNA for a total input of 3 μg DNA (for fragmentation and library preparation) using the expanded RNA bait library and Agilent SureSelectXT protocol. Total C. trachomatis genome copy input ranged from 265 to 7,854,406 copies, which is similar to the range for genome copies from clinical samples (see below), with 1.33 to 99.28% of the quality-controlled reads binned as Chlamydia species, along with a mean mapping read depth to the C. trachomatis reference genome ranging from 0.57 to 562.67, respectively (Table 1; Fig. 1; also, see Fig. S1 in the supplemental material). With the quality control (QC) criteria for efficiency set at ≥98% genome coverage at a ≥5× read depth, genotype D had an LOD of 16,945 total genome copies (Table 1; Fig. 1).

Enrichment and genomic sequencing of C. trachomatis from genotype L2b and patient specimen sets. To ensure efficiency of target enrichment from a C. trachomatis ompA genotype prevalent in anorectal infections in HIV-infected MSM, genomic libraries from spiked mock samples of genotype L2b were prepared, enriched for C. trachomatis, and sequenced. Total C. trachomatis genome copy input ranged from 9,000 to 900,000 copies, with 97.22 to 98.77% of the quality-controlled reads binned as Chlamydia species along with a mean mapping read depth to the C. trachomatis reference genome ranging from 531.81 to 550.78, respectively (Table 2; Fig. S2).

To determine efficiency of target enrichment from vaginal and rectal clinical specimens, C. trachomatis was directly sequenced from 4 sets of patient-matched vaginal and rectal swabs. The ranges of copy numbers by qPCR were 328 to 2,218 genomes per μl for the vaginal samples and 1,664 to 43,905 genomes per μl for the rectal samples. Total input ranged from 20,764 to 3,336,780 C. trachomatis genome copies. More genome copies were present in the rectal swab than in the vaginal swabs in 3 of the 4 patient specimen sets (Table 2). As with the spiked gDNA serial dilutions, the proportion of reads classified as Chlamydia spp. from clinical samples was dependent on total genome copy input (Table 2; Fig. 2).

For three of the four patient specimen sets (sets 107, 192, and 98), 18.07%, 30.82%, and 17.13% more reads were classified, respectively, as Chlamydia spp. in the rectal swab than the respective vaginal swab (Table 2; Fig. 2). Interestingly, for patient specimen set 72, there were 32.94% more Chlamydia reads in the vaginal swab, which contained 68,201 more genome copies than the rectal swab (Table 2; Fig. 2). Mean read depth was on average 3.5-fold higher in rectal swabs from patient specimen sets 107, 192, and 98, while patient specimen set 72 demonstrated a 3.3-fold-higher mean read depth in the vaginal swab (Table 2; Fig. S2). For all patient specimen sets, the percentage of the C. trachomatis genome covered with at least 5× coverage was >98%, with the exception of 72R, which had only 96.11% of the genome covered at a minimum of 5× read depth.
| Sample ID | ompA genotype | C<sub>a</sub> | Total no. of genome copies input | C. trachomatis ompA | Total no. of raw read pairs | Nonhuman read pairs | Total mean read depth | % of genome with coverage | % of genome with coverage
|------------|----------------|----------------|----------------------------------|----------------|--------------------------|--------------------|------------------------|--------------------------|------------------------|--------------------------|
| D1         | D              | 18.29          | 7,854,406                        | 2,136,708       | 2,118,719                | 0.99               | 2,095,052                  | 99.28                    | 562.67                  | 99.02                    | 99.01                    |
| D2         | D              | 22.01          | 942,398                          | 1,482,054       | 1,382,594                | 0.93               | 1,335,421                  | 98.73                    | 359.60                  | 99.02                    | 99.01                    |
| D3         | D              | 27.58          | 39,392                           | 1,115,066       | 729,165                  | 0.65               | 667,101                   | 93.54                    | 169.14                  | 99.02                    | 98.95                    |
| D4         | D              | 29.055         | 16,945                           | 1,117,188       | 277,491                  | 0.25               | 237,908                   | 65.54                    | 42.22                   | 98.69                    | 97.66                    |
| D5         | D              | 32.15          | 1,876                            | 1,955,298       | 219,077                  | 0.11               | 162,471                   | 17.24                    | 7.47                    | 70.29                    | 29.16                    |
| D6         | D              | 36.345         | 265                              | 1,509,294       | 189,690                  | 0.13               | 159,750                   | 1.33                     | 0.57                    | 0.73                     | 0.006                    |

<sup>a</sup>C<sub>a</sub>, cycle threshold based on C. trachomatis ompA RT-PCR (62). Cycle threshold is the cycle number at which the fluorescence generated within a reaction crosses the fluorescence threshold determined for the assay.

<sup>b</sup>With a quality score of ±15.

<sup>c</sup>After quality control, i.e., deduplication and adapter trimming.

<sup>d</sup>Selected for Chlamydia spp. and C. trachomatis read pairs.

<sup>e</sup>With rRNA masked.
Phylogeny and single nucleotide polymorphisms among patient specimens. To ensure that genomes generated from the four patient specimen sets clustered to any of the four deep-branching monophyletic *Chlamydia trachomatis* lineages, a whole-genome phylogenetic analysis was constructed with 94 *C. trachomatis* single-contig genome sequences that were available from GenBank in December 2019 (Table S2) (40, 42, 54). Both the genomes from patient specimen sets 107 and 192 clustered within the “prevalent urogenital and rectal strain” clade, while patient specimen sets 98 and 72 clustered within the “nonprevalent urogenital and rectal strain” clade (Fig. 3).

Patient genomes 107 and 192 clustered in the same clade as the E genotype genomes (prevalent urogenital and anorectal lineage), whereas patient genomes 98 and 72 clustered in the same clade as G *ompA* genotypes (nonprevalent urogenital and anorectal lineage) (Fig. 3). For all four patients, the genomes derived from the two body sites formed distinct monophyletic clades within their respective urogenital lineage with a mean difference of 3 single nucleotide polymorphisms (SNPs) (1 to 5 SNPs), indicating that each patient likely carried the same strain within her rectum and vagina (Fig. 3; Table 3). Interestingly, five within-host SNPs were identified in patient 72, and 2 of these SNPs were within the highly recombinogenic *ompA* (2 SNPs) and *pmpF* (2 SNPs) genes. Genomic comparison of all the plasmids against all reference plasmid sequences showed that there was 100% sequence similarity within each patient specimen set (e.g., sample sets 107 and 192 had E plasmids in both anatomic sites) with the exception that the vaginal plasmid from patient 192 had a single nucleotide deletion at nucleotide position 5241 compared to the rectal plasmid. This deletion was within a gene that encodes a hypothetical protein. No other indels or SNPs were noted in any of the plasmids.

Detection of recombination events from genomes derived from patient specimens. Patient specimen sets harbored a total of 14 putative recombination blocks that contained between 21 and 419 homoplasic SNPs thought to have been introduced via homologous recombination. The number of putative recombination blocks varied between 1 and 6 within a patient specimen set, covering an average 12.2-kb region per specimen (Table S3). All the putative recombination blocks identified and described were shared within and detected only in each of the patient specimen sets, indicating that these recombination events were ancestral and acquired through clonal descent. Among the patient specimen sets, 107R and 107V (urogenital prevalent lineage) had the highest rates of recombination (\( r/\theta = 0.111 \)) as well as increased effects of recombination over point mutations (\( r/m = 5.777 \)) followed by patient specimen sets 72R and 72V (urogenital nonprevalent lineage; \( r/\theta = 0.053; \ r/m = 3.803 \)). The lowest number of recombination events were observed among the
## Table 2: Sequence data analysis of C. trachomatis gDNA extracted from spiked mock samples of genotype L2b and patient specimen sets

| Sample ID | ompA genotype | Total no. of genome copies input | No. of: | Nonhuman read pair ratio | No. of: | % selected read pairs | Mean read depth | % of genome with coverage |
|-----------|----------------|----------------------------------|---------|--------------------------|---------|-----------------------|----------------|--------------------------|
|           |                | Raw read pairs | Nonhuman read pairs | Total read pairs after QC | Selected read pairs |                      |                |                          |
|           |                |                   |                    |                          |                |                      |                |                          |
| L1        | L2b            | 900,000           | 2,099,167          | 2,079,997                | 0.99          | 2,067,413             | 550.78         | 98.98                    | 98.97 |
| L2        | L2b            | 90,000            | 2,239,718          | 2,206,788                | 0.99          | 2,189,496             | 564.40         | 98.98                    | 98.97 |
| L3        | L2b            | 9,000             | 2,230,573          | 2,108,624                | 0.95          | 2,045,830             | 531.81         | 98.97                    | 98.94 |
| 107R      | Ja             | 1,378,275         | 2,302,152          | 2,051,954                | 0.89          | 1,924,399             | 190.25         | 98.91                    | 98.89 |
| 107V      | Ja             | 177,440           | 1,347,716          | 1,048,957                | 0.78          | 942,944               | 47.15          | 98.84                    | 98.67 |
| 192R      | Ja             | 3,336,780         | 2,175,904          | 1,937,403                | 0.89          | 1,793,255             | 313.09         | 98.92                    | 98.91 |
| 192V      | Ja             | 28,536            | 1,390,989          | 1,040,223                | 0.75          | 940,352               | 90.23          | 98.91                    | 98.90 |
| 72R       | G              | 121,472           | 1,764,699          | 1,652,600                | 0.94          | 1,429,554             | 13.99          | 96.11                    | 74.60 |
| 72V       | G              | 189,673           | 1,568,358          | 556,417                  | 0.35          | 463,667               | 46.16          | 98.82                    | 98.55 |
| 98R       | G              | 2,460,822         | 1,930,840          | 1,822,417                | 0.94          | 1,715,197             | 261.91         | 98.94                    | 98.86 |
| 98V       | G              | 20,764            | 1,259,385          | 856,804                  | 0.68          | 791,372               | 84.58          | 98.88                    | 98.64 |

*R, rectal swab; V, vaginal swab.

*With a quality score of ≥15.

*After quality control, i.e., deduplication and adapter trimming.

*Down-selected for *Chlamydia* spp. and *C. trachomatis* read pairs.

*With rRNA masked.
98V and 98R patient specimen sets (nonprevalent lineage; $\rho/\theta = 0.031$; $r/m = 0.6562$) (Table S3).

Some of the previously identified genomic regions of higher homologous recombination were also identified in this study. The *ompA* gene has undergone recombination in both prevalent urogenital patient specimen sets 107 and 192. *ompA* genotyping by both Sanger sequencing and whole-genome data indicated that the *ompA* genotype of specimens from patients 107 and 192 was Ja within an E genome backbone. Our recombination detection analysis showed that homologous recombination might have mediated the transfer of an ~12.9-kbp fragment containing CT_681/*ompA* along with the neighboring genes (from type III secretion system protein gene [CT_672] to *pbpB* [CT_682]) into patient 192 and a larger fragment of 17.6 kbp from CT_672 to *pbpB* (CT_682) along with *ompA* into patient 107, likely from a Ja strain (Fig. 3; Table S3). The *pmpE* and *mrsA_1* genes were estimated to be recombinant, respectively, in sets 107 and 192 (40, 54). The inclusion membrane protein gene *incD* was predicted to be recombinant only in the nonprevalent urogenital patient specimen set 98. (Table S3) (40, 54).

**DISCUSSION**

A SureSelectXT workflow with a 2.698 Mbp RNA bait library with 34,795 120-mer probes was developed from 85 GenBank *C. trachomatis* reference genomes encompassing all four lineages of *C. trachomatis*, compared to the previous RNA bait library developed from 74 GenBank *C. trachomatis* reference genomes with 33,619 120-mer probes (52). By including more *C. trachomatis* reference genomes in our bait library design, which generated 1,000+ more probes, we likely captured more genetic diversity of the *C. trachomatis* strains circulating in the population than the RNA baits generated previously by Christiansen et al. (52). Moreover, having >98% of the *C. trachomatis* reference genome covered with at least 10 reads per nucleotide position for clinical specimens (with an exception for specimen 72R) indicates that the probes were uniformly covered along the *C. trachomatis* genome. Compared to a previous study that obtained 98% coverage with a total input of 4,800 *C. trachomatis* strain F/SW4 genome.
copies (52), we report an LOD of around 16,000 total genomes at 98% coverage for *C. trachomatis* reference strain D/UW-3/Cx. This LOD was within the same order of magnitude as that in the previous study, although we utilized an expanded RNA bait library, a different assay to determine copy number (i.e., quantitative real-time PCR [qRT-PCR] versus qPCR), and gDNA from a spiked sample versus a sample that had been propagated in tissue culture.

Here, it was useful to calculate comparable mean read depths and the number of down-selected read pairs among the spiked samples of L2b, as this demonstrates success in enrichment for LGV strains, which have become prevalent among MSM and MSW (23, 25, 27, 28). Phylogenetic analysis of the 94 reference genomes (of which 85 genomes were used to develop the RNA bait library) showed genome representation from all four *C. trachomatis* lineages (Fig. 3). Overall, this workflow was successful in enrichment and sequencing of *C. trachomatis* strains that are prevalent in anorectal infections from two different populations: the MSM population, from which L2b originated, and the female heterosexual population, from which the paired vaginal and rectal samples originated.

Sequence data analysis of patient specimen vaginal and rectal swabs sets revealed successful enrichment and genome sequencing of *C. trachomatis* from both clinical specimen types. In three of the four patient specimen sets, sequencing was more efficient for the rectal swabs, likely due to the higher genome copy number of *C. trachomatis* for those specimen sets. With a total input of 3,336,780 *C. trachomatis* genome copies, rectal specimen 192 demonstrated the best enrichment, with 89% nonhuman
reads, of which 66.07% belonged to *Chlamydia* species that mapped to 98.92% of the *C. trachomatis* reference E strain genome with at least 10 reads per nucleotide position and with a mean read depth coverage of 313.09. This is an improvement over a previous study that subjected clinical urine and vaginal samples to the prior Agilent bait library, where the best sample had 49.57% of the reads belonging to *Chlamydia* species, with 99.9% mapping to the reference D genome at a mean read depth of 410 from a total input of 68,864,400 *C. trachomatis* genome copies (52). Unfortunately, the number of reads mapped per nucleotide position to achieve the 99.9% coverage was not provided. Overall, enrichment of *C. trachomatis* from the samples in that study was successful in only eight (80%) of 10 samples, for a genome coverage of ≥95 to 100% for the respective reference genome; the percentage of reads mapping to the respective reference genome used for calling the SNPs was 95 to 100% genome coverage (55), again without reads mapped per nucleotide position to achieve the genome coverage of ≥95 to 100%, we cannot make a direct comparison of the efficiencies of the bait library in this study compared to the previous *C. trachomatis* bait library.

In another study using the prior Agilent bait library, only 12 (60%) of 20 clinical ocular samples reached ≥95 to 100% genome coverage (55), again without reads mapped per nucleotide position. In our study, all eight (100%) clinical samples reached ≥95 to 100% genome coverage, with reads mapping to *C. trachomatis* ranging from 3.71 to 98.77%, indicating that this probe library—which further excludes baits with human homology—can achieve the desired efficiency.

The higher *C. trachomatis* bacterial load detected in rectal specimens in three of the four patient specimen sets conflicts with two studies that demonstrated similar loads across sets of vaginal and anorectal specimens collected from the same women with and without anal intercourse visiting an STI clinic in the Netherlands and in a high-HIV-prevalence area in South Africa (57, 58). For our study, the trend may be a characteristic of the assay used to determine copy number or the study population itself or, because of the small sample size, may not be representative of the study population as a whole. Nevertheless, Dirks et al. (59) pointed out the ineffectiveness of comparing load across *C. trachomatis* surveillance studies due to the lack of standardization for load determination and the presence of inflammatory cells which can artificially lower the number of *C. trachomatis* load. However, it is useful to determine the bacterial load in patient specimens to ensure that enough gDNA is present to successfully enrich for *C. trachomatis* in a target enrichment sequencing workflow, although conclusions should not be drawn from this estimated value about severity of infection, associated symptoms, or transmission.

### TABLE 3 SNPs detected within patient specimen sets

| Patient specimen seta | Gene containing within-host SNPs | No. of SNPs | Genome location(s) (SNP and nucleotide coverage for each variant) | Reference genome used for calling the SNPsb |
|-----------------------|---------------------------------|-------------|---------------------------------------------------------------|---------------------------------------------|
| 107R and 107V         | Gene for hypothetical protein (FSW4_RS00260) | 1           | 54906 (C→T; T:62, C:1) | F/SW4 (NC_017951.1) |
|                       | Gene for hypothetical protein (FSW4_RS00270) | 2           | 59520 (T→C; C:33, T:0), 59523 (C→T; T:33, C:0) | F/SW4 (NC_017951.1) |
|                       | Intergenic region                | 1           | 79002 (G→A; A:77, G:0) | F/SW4 (NC_017951.1) |
|                       | Gene for amino acid ABC transporter ATP-binding protein | 1           | 146249 (C→T; T:145, C:0) | F/SW4 (NC_017951.1) |
| 192R and 192V         | Gene for PTS sugar transporter subunit IIA | 1           | 437237 (T→C; C:36, T:0) | F/SW4 (NC_017951.1) |
| 72R and 72V           | *ompA*                           | 2           | 779230 (G→A; A:33, G:1), 779235 (C→A; A:31, G:2) | D/UW-3/CX (NC_000117.1) |
|                       | Gene for hypothetical protein (CT_744) | 1           | 864903 (T→C; C:50, T:0) | D/UW-3/CX (NC_000117.1) |
|                       | *pmpF*                           | 2           | 1029641 (G→T; T:75, G:0), 1029643 (A→G; G:75, A:0) | D/UW-3/CX (NC_000117.1) |
| 98R and 98V           | Gene for hypothetical protein (CT_049) | 1           | 54281 (C→T; T:23, C:0) | D/UW-3/CX (NC_000117.1) |

aR, rectal; V, vaginal.
bSNPs were called by comparing the genomes of patient specimen sets to reference genomes that clustered in the whole-genome phylogenetic tree.
Genomes derived from each patient specimen set were located phylogenetically within the representative lineages of their respective strain genotype as determined by Sanger sequencing, demonstrating success of the workflow and bioinformatic analysis described here. Although overall genome coverage was determined using conservative read depths ($5\times$ and $10\times$), a small number of SNPs were identified within patient sample sets at a range of 23 to 145x coverage, demonstrating low genome diversity within a single patient with a low probability of false positives and negatives. Interestingly, patient specimen sets 107 and 192 were associated with the prevalent strain lineage, a recent urogenital lineage that has been suggested to have been derived from recombination (40, 54). Further, the detection of recombination involving ompA, a known hot spot for recombination in the C. trachomatis genome, in these samples as part of an approximately 12-kb exchange event, in addition to four and five other recombination blocks, respectively, could be identified only by whole-genome sequencing (WGS) and not by Sanger sequencing alone or with traditional molecular typing methods such as ompA genotyping, MLST, or MLVA (40, 43, 54). In contrast, patient specimen sets 72 and 98 had three and one recombination blocks, respectively. These data highlight the genetic resolution achieved by our workflow. Indeed, the circulation of two different C. trachomatis lineages with various degrees of recombination across the genomes in a single population is of interest and displays the complexity of C. trachomatis strain evolution and transmission. Furthermore, the novel finding that vaginal and rectal pairs have the same genomes suggests within-host transmission, indicating the need for larger studies to further explore this possibility.

Here, we describe a higher-efficiency target enrichment bait library and a workflow that streamlines the molecular characterization of C. trachomatis from rectal as well as vaginal specimens. This type of high-resolution data can be used to understand the genetic diversity of current C. trachomatis strains causing genital and rectal infections and provide a robust molecular epidemiologic approach to advance our understanding of geosexual networks, outbreaks of colorectal infections among women and men who have sex with men, and the role of these strains in morbidity. The bioinformatic pipeline can further be used to potentially identify novel markers for typing C. trachomatis and to examine the microbiome to determine the role it plays in susceptibility, transmission and clearance of urogenital and rectal C. trachomatis infections, especially given the need for a longer duration of therapy for rectal infections than for most uncomplicated urogenital infections (60, 61). Finally, the bait library is publicly available, which will support comparative genome studies going forward.

MATERIALS AND METHODS

**Spiked serial dilutions of C. trachomatis reference strain D/UW-3/Cx.** Genomic DNA (gDNA) from C. trachomatis reference strain genotype D/UW-3/Cx (ATCC VR-885D) was used to determine the limit of detection (LOD) for this workflow. The LOD was set at the minimal genome copy number required to generate a ≥5× read depth with ≥98% genome coverage compared to the reference strain of the same ompA genotype. Six 100-μl serial dilutions (10⁻¹ to 10⁻⁵) were prepared by spiking into 1× phosphate-buffered saline (PBS). A standard curve based on ATCC’s reported copy number for genotype L2b (ATCC VR-9028D) was generated using real-time PCR (RT-PCR) targeting the C. trachomatis single-copy polymorphic membrane protein gene pmpH (62). This standard curve ($y = 1 \times 10^{m - 0.022c}; R^2 = 0.987$) was then used to calculate a more precise genome copy number for each serial dilution of genotype D.

**Spiked mock samples of C. trachomatis genotype L2b.** gDNA from C. trachomatis clinical strain genotype L2b (ATCC VR-9028D) was used to ensure success of this workflow with a C. trachomatis strain prevalent in anorectal infections in HIV-infected MSM. Three 100-μl serial dilutions (9,000 to 900,000 total genome copies) were prepared by spiking into 1× PBS, all within the LOD established using C. trachomatis reference strain genotype D.

**C. trachomatis clinical specimens and determination of C. trachomatis genome copy number.** Clinical urogenital and rectal samples were obtained from women aged 18 to 40 years who were at high risk for STIs after giving informed consent as part of a separate study that was approved by the institutional review board of UCSF Benioff Children’s Hospital Oakland Research Institute. For this study, the samples were stripped of all personal identifiers with no trace to the patient names. FLOQswab vaginal and rectal swabs (Copan, Murrieta, CA) had been collected using standard techniques by trained clinic staff and screened for C. trachomatis using the Xpert CT/NG test (Cepheid, Sunnyvale, CA). Four clinical vaginal samples and the four paired rectal swabs from the same four women (randomly selected using a...
Approximately 200 µl of remnant swab collection buffer that had not been run in the Xpert test was lysed with 59 µl of a cocktail consisting of 50 µl lysozyme (10 mg/ml; MilliporeSigma, St. Louis, MO), 3 µl of lysostaphin (4,000 U/ml in sodium acetate; MilliporeSigma), and 6 µl of mutanolysin (25,000 U/ml; MilliporeSigma) for 1 h at 37°C as described elsewhere (63). gDNA was then purified from the lystate using the QIAamp DNA minikit (Qiagen) according to the manufacturer’s instructions. For rectal swabs collected in M4 medium (Thermo Fisher, South San Francisco, CA), 200 µl was treated as described above.

gDNA was subjected to an in-house qPCR to quantitate the genomic copy number of C. trachomatis as we previously described (64). Briefly, primers flanking the ompA gene were used for PCR. The PCR product was purified by exonuclease-I (Thermo Fisher) and subjected to Sanger sequencing using the PCR primers (65). Forward and reverse sequences were aligned using MAFFT v7.450 (66) to create a consensus sequence that was aligned to all reference ompA genotypes. The reference strains included A/HAR-13, B/TW-5/OT, Ba/Apache-2, C/TW-3/OT, D/UW-3/Cx, Da/TW-448, E/Bour, F/IC-Cal-13, G/UW-57/Cx, H/UW-4/Cx, I/UW-12/Ur, J/UW-202, J/UW-36/Cx, Ja/UW-92, K/UW-31/Cx, L, L/343, L/a/UW-396, L/b/UUCH-1/ proctitis, L/c, and L/d-404.

Five overlapping PCR primer pairs were designed using the IDT PrimerQuest tool (https://www.idtdna.com/pages/tools/primerquest) to amplify the entire plasmid (Table 5). The thermocycling parameters were 3 min at 95°C followed by 40 cycles of 95°C for 30 s, 56°C for 30 s, and 72°C for 1 min 10 s with a final incubation at 72°C for 7 min. The PCR product was purified and sequenced as described above, and the consensus sequence was aligned to all reference plasmid sequences as described above using MAFFT v7.450.

Quantification and fragmentation. Samples were quantified using a Qubit 2.0 fluorometer, and human gDNA (Promega, San Luis Obispo, CA) was added to reach a total input of 3 µg/130 µl for fragmentation and library prep. Samples were sheared on a Covaris LE220-plus instrument using the 8 microTUBE strip VT (PN 520053; Covaris, Woburn, MA) with the base pair mode set to 250 to 300 bp following the manufacturer’s instructions.

RNA bait library design. A 2.698 Mbp RNA bait library consisting of 34,795 120-mer probes spanning 85 GenBank C. trachomatis reference genomes was designed using Agilent SureDesign. No plasmid probes were included in the RNA bait library construction. The bait library was synthesized by Agilent Technologies. Although Agilent Technologies prevents publication of the probe sequences for the RNA bait libraries they design, the custom-designed RNA bait library (ELID 3173001) used in this study can be retrieved by contacting Agilent Technologies, Inc. (Santa Clara, CA). The sequences for the bait library developed by Christiansen et al. (52) and the bait library itself are not publicly available, resulting in the inability to compare it with the RNA bait library designed in this study. Sequencing of the RNA bait library itself was not necessary, as Agilent provided the probe sequences, which were analyzed using BLAST to determine that they represented all C. trachomatis genovars.

Library prep. After shearing, the SureSelectXT target enrichment system for Illumina paired-end multiplexed sequencing library (VCZ, December 2018) and all recommended quality control steps were performed on all gDNA samples. A 16-h incubation at 65°C was performed for RNA bait library hybridization. Postcapture PCR cycling was set at 12 cycles based on a capture library size of >1.5 Mb.

Illumina MiSeq sequencing. The eight clinical samples were multiplexed for two runs of paired end sequencing on an Illumina MiSeq instrument using a 300-bp v2 reagent kit. For the final multiplexed library pool, libraries were diluted to 2 nM/3 µl in low-EDTA Tris-EDTA buffer (TE) for a final concentration of 10 pM; 12.5 pM PhiX was added to the final pool that was loaded onto the MiSeq sequencer.

Sequence and phylogenetics analysis. Host genome sequences were first filtered from the raw sequencing data set using Bowtie2 version 2.2.9 (67), which removed any contaminating human sequences using the h19 human reference genome (68). Cutadapt version 1.8.3 (69) was used to trim specified primers and adapters and to filter out reads below Phred quality scores of 15 and read length below 50 bp. Duplication of the reads was performed using Clumpify (sourceforge.net/projects/bbmap/) with the dedupe-t option to prevent biased coverage of genomic regions. C. trachomatis sequencing reads were selected using K-SLAM (70), a k-mer-based metagenomics taxonomic profiler, which used a database containing all bacterial and archaeal reference nucleotide sequences. The presence of C. trachomatis sequences was also confirmed using Metaphlan2 (71). We generated a custom version of the C. trachomatis D/UW-3/CX reference sequence (NC_000117.1) from which we masked 6 rRNA genes, CT_r01 (16SrRNA_1), CT_r02 (23SrRNA_1), CT_r03 (5SrRNA_1), CT_r04 (16SrRNA_2), CT_r05 (23SrRNA_2), and CT_r06 (5SrRNA_2), present in the repeated rRNA operons using the bedtools v2.17.0 (72) tool “mask-fasta.” Prefiltered chlamydiyal reads were mapped against this custom reference genome using BWA mem v2.12.0 (73) (MapQ ≥ 20), followed by consensus genome generation and estimation of sequencing depth and mapping statistics using SAMtools (74) (options “depth” and “mpileup”) and bcftools v1.9. The prefiltered C. trachomatis sequencing reads were also used to generate de novo short-read assemblies using SPAdes 3.7.0 (75) with the “careful” option. To genotype the patient samples, de novo contigs were used to extract and compare the ompA genes against a customized BLAST (76) database of the 21 reference ompA sequences (see above). The equation used to calculate mean read depth was: number of mapped reads × average bp read length/(bp length of CT reference genome).
For phylogenetic analysis, apart from the patient genome sequences \((n=8)\), we also included all \(C.\ trachomatis\) genomes (without plasmid sequences) available in NCBI \((n=94)\) and used a reference mapping approach with the above-mentioned custom version of the \(C.\ trachomatis\) D/UW-3/CX reference genome sequence. In short, full-length whole-genome alignments were generated using Snippy v3.1 (https://github.com/tseemann/snippy), which identifies variants using Freebayes v1.0.2 (77) with a minimum 10× read coverage and 90% read concordance at a locus for each SNP. Regions of increased density of homoplasious SNPs introduced by possible recombination events were predicted iteratively and masked using Gubbins (78). The final phylogenetic tree was reconstructed using RaxML (79) on the recombination removed alignment using the general time-reversible (GTR) model. The genes located within the putative recombination blocks for the patient samples were identified by comparing the alignment genomic coordinates for the predicted recombination blocks to the gene annotations of the reference genome. Within-host SNP differences were derived from the alignment before masking the predicted recombination events.

**Data availability.** All sequencing data associated with this study were submitted to the National Center for Biotechnology Information’s sequence read archive (SRA) under the BioProject accession ID PRJNA609714.

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**FIG S1**, PDF file, 0.2 MB.

**FIG S2**, PDF file, 0.2 MB.

**TABLE S1**, XLSX file, 0.01 MB.

**TABLE S2**, XLSX file, 0.01 MB.

**TABLE S3**, XLSX file, 0.02 MB.

**ACKNOWLEDGMENTS**

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

This work was made possible through support from CDC’s Advanced Molecular Detection (AMD) program. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

We thank Sankhya Bomanna for excellent technical assistance.

K. E. Bowden transcribed the manuscript and generated the genomic libraries from the serial dilutions and clinical specimens for sequencing and analysis. S. J. Joseph performed the bioinformatics analysis, conducted phylogenetic analysis of the genomic data, and contributed to the writing of the manuscript. J. C. Cartee pooled and sequenced the genomic libraries on the MiSeq system. N. Ziklo prepared and purified the gDNA from the clinical samples and performed the qPCR and fragmentation for library preparation. D. Danavall prepared spiked gDNA serial dilutions for LOD determination. B. H. Raphael oversaw the project within CDC and provided technical support and subject matter expertise on the genome sequencing workflow and bioinformatic analysis. T. D. Read conducted initial phylogenetic analysis while providing continued technical support and subject matter expertise for the data analysis. D. Dean collected and provided the patient specimens and provided technical support and subject matter expertise on the genome sequencing workflow and contributed to the writing of the manuscript. All authors reviewed, edited, and contributed to the manuscript.

We declare no competing interests.

**REFERENCES**

1. Centers for Disease Control and Prevention. 2014. Recommendations for the laboratory-based detection of \(Chlamydia trachomatis\) and Neisseria gonorrhoeae--2014. MMWR Recomm Rep 63:1–19.

2. Stamm WE. 2011. \(Chlamydia trachomatis\) infections of the adult. In Holmes KK (ed), Sexually transmitted diseases, 4th ed, p 575–606. McGraw Hill Professional, New York, NY.

3. Dean D, Schachter J, Dawson CR, Stephens RS. 1992. Comparison of the major outer membrane protein variant sequence regions of B/Ba isolates: a molecular epidemiologic approach to \(Chlamydia trachomatis\) infections. J Infect Dis 166:383–392. https://doi.org/10.1093/infdis/166.2.383.

4. Isaksson J, Carlsson O, Airell A, Stromdahl S, Bratt G, Hermann B. 2017. Lymphogranuloma venereum rates increased and \(Chlamydia trachomatis\) genotypes changed among men who have sex with men in Sweden 2004-2016. J Med Microbiol 66:1684–1687. https://doi.org/10.1099/jmm.0.000597.

5. Spaargaren J, Fennema HS, Morre SA, de Vries HJ, Coutinho RA. 2005. New lymphogranuloma venereum \(Chlamydia trachomatis\) variant,
Amsterdam. Emerg Infect Dis 11:1090–1092. https://doi.org/10.3201/ eid1107.040883.

6. Spaargaren J, Schachter J, Moncada J, de Vries HJ, Fennema HS, Pena AS, Coutinho RA, Morre SA. 2005. Slow epidemic of lymphogranuloma venereum L2b strain. Emerg Infect Dis 11:1787–1788. https://doi.org/10.3201/eid1111.050821.

7. Christerson L, de Vries HJ, van der Ende A, van der Bruggen B, Herrmann B. 2006. Lymphogranuloma venereum and HIV: an association in men who have sex with men: systematic review and meta-analysis. BMC Infect Dis 11:70. https://doi.org/10.1186/1471-2334-11-70.

8. Chan PA, Robinette A, Montgomery M, Almonte A, Cu-Uvin S, Lonks JR, Chapin KG, Kojic EM, Hardy EJ. 2016. Extragential infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol 2016;5758387. https://doi.org/10.1155/2016/5758387.

9. van Liere GA, van Rooijen MS, Hoebe CJ, Heijman T, de Vries HJ, Dukers-Muijters NH. 2015. Prevalence of and factors associated with rectal-only chlamydia and gonorrhoea in women and in men who have sex with men. PLoS One 10:e0140297. https://doi.org/10.1371/journal.pone.0140297.

10. Poon Lim NL, Broad C, Hay J, Besier EM, Woodhall SC, Saunders JM, Sadig ST, Dunbar JK. 2018. Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis. Sex Transm Infect 94:320–326. https://doi.org/10.1136/sxtr-2017-053611.

11. Daniëls CB, Cosentino LA, Rabe LB, Priest CL, Damare KC, Macio IS, Meyn LA, Wiesenfeld HC, Hillier SL. 2016. Patterns of extragenital chlamydia and gonorrhoea in women and men who have sex with men reporting a history of receptive anal intercourse. Sex Transm Dis 43:105–109. https://doi.org/10.1093/ctd/ctv127.

12. Bax CJ, Quint KD, Peters RP, Ouburg S, Oostvogel PM, Mutsaers JA, Dorr PJ, Schmidt S, Jansen C, van Leeuwen AP, Quint WG, Trimbos JB, Meijer CJ. 2016. No indication for tissue tropism in urogenital and anorectal Chlamydia trachomatis infections using high-resolution multilocus sequence typing. BMC Infect Dis 14:464. https://doi.org/10.1186/1471-2334-14-464.

13. van der Helm JJ, van der Molen L, van der Knaap AM, van der Poel JA, van der Ende A, van der Poel JJ, van der Poel JW. 2010. Typing of lymphogranuloma venereum networks of Chlamydia trachomatis. Emerg Infect Dis 16:1777–1784. https://doi.org/10.3201/eid1611.100351.

14. Ronn WM. 2011. The association between lymphogranuloma venereum and HIV in men who have sex with men: systematic review and meta-analysis. BMC Infect Dis 11:70. https://doi.org/10.1186/1471-2334-11-70.

15. Klint M, Lofdahl M, Aarell T, Berglund T, Herrmann B. 2004. Characterization of ompA genotypes by sequence analysis from all detected cases of Chlamydia trachomatis infections during 1 year of contact tracing in a Swedish county. J Clin Microbiol 42:1641–1647. https://doi.org/10.1128/JCM.42.4.1641-1647.2004.

16. Morre SA, Rozendaal L, van Valkengoed IG, Boeke AJ, van Voorst Vader C, Schmidt S, Jansen C, van Leeuwen AP, Quint WG, Trimbos JB, Meijer CJ, Morre SA. 2014. Highly diverse MLVA-ompA genotypes of rectal Chlamydia trachomatis among men who have sex with men in Brighton, UK and evidence for an HIV-related sexual network. Sex Transm Infect 92:299–304. https://doi.org/10.1136/sextrans-2015-052261.

17. van der Ende A, van der Poel JA, van der Poel JJ, van der Poel JW. 2010. Typing of lymphogranuloma venereum networks of Chlamydia trachomatis. Emerg Infect Dis 16:1777–1784. https://doi.org/10.3201/eid1611.100351.

18. Ronn WM. 2011. The association between lymphogranuloma venereum and HIV in men who have sex with men: systematic review and meta-analysis. BMC Infect Dis 11:70. https://doi.org/10.1186/1471-2334-11-70.

19. Stark D, van Hal S, Hillman R, Harkness J, Marriott D. 2007. Lymphogranuloma venereum in heterosexual adults in Amsterdam, The Netherlands. PLoS One 8:e53869. https://doi.org/10.1371/journal.pone.00053869.

20. Young J, King J, Gray RR, Wight E, Cheng H, Mathison C, Popovic S, Pope C, Ge X, Shaw GD, et al. 2011. Development of rapid diagnostic tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol 48:1827–1832. https://doi.org/10.1128/JCM.02398-09.

21. Labiran C, Gaspar V, Squibb P, Salvo M, D’Antuono A, Marangoni A. 2018. Sexually transmitted rectal infections in a cohort of ‘men having sex with men’. J Med Microbiol 67:1050–1057. https://doi.org/10.1099/jmm.0.000781.

22. van der Heije NJ, van der Poel JA. 2014. Lymphogranuloma venereum among men who have sex with men. An epidemiological and clinical review. Expert Rev Anti Infect Ther 12:697–704. https://doi.org/10.1586/14787210.2014.901169.

23. Pannekoek Y, Morelli G, Kusecek B, Morre SA, Ossewaarde JM, Langerak AW, de Vries HJ, Boom RM, van der Poel JA, van der Poel JW. 2016. Diverse molecular epidemiology of repeat Chlamydia trachomatis infection in the population of Southampton attending the genitourinary medicine clinic in 2012-13 reveals the presence of long established genotypes and transitory sexual networks. PLoS One 12:e0185059. https://doi.org/10.1371/journal.pone.0185059.

24. Dean D, Bruno WJ, Wan R, Gomes JP, Devignot S, Mehari T, de Vries HJ, Morre SA, Myers G, Read TD, Sparrt BG. 2009. Predicting phenotype and emerging strains among rectal Chlamydia trachomatis in samples from heterosexual couples. J Clin Microbiol 47:1385–1394. https://doi.org/10.1128/JCM.02301-06.2016/5758387.

25. Pannekoek Y, Kurellis P, Hocking JS. 2014. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 59:193–205. https://doi.org/10.1093/cid/ciu920.

26. Bakker LM, Berends J. 2013. Azithromycin for chlamydia and gonorrhoea: a review and meta-analysis. J Clin Microbiol 51:1331–1336. https://doi.org/10.1128/JCM.02483-14.

27. Lim C, Hook EW. 2010. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol 48:1827–1832. https://doi.org/10.1128/JCM.02398-09.

28. van der Ende A, van der Poel JA, van der Poel JJ, van der Poel JW. 2010. Typing of lymphogranuloma venereum networks of Chlamydia trachomatis. Emerg Infect Dis 16:1777–1784. https://doi.org/10.3201/eid1611.100351.

29. Ronn WM, Hendriksen R, van der Poel JA, van der Poel JW. 2010. Typing of lymphogranuloma venereum networks of Chlamydia trachomatis. Emerg Infect Dis 16:1777–1784. https://doi.org/10.3201/eid1611.100351.
Comprehensive global genome dynamics of Chlamydia trachomatis show ancient diversification followed by contemporary mixing and recent lineage expansion. Genome Res 27:1220–1229. https://doi.org/10.1101/gr.212647.116.

Alkhidir AA, Holland MJ, Elhag W, Williams CA, Breuer J, Elemam AE, El Hussain KMK, Oumasseur MEH, Pickering H. 2019. Whole-genome sequencing of ocular Chlamydia trachomatis isolates from Gadafar State, Sudan. Para- sit Vectors 12:518. https://doi.org/10.1186/s13071-019-3770-7.

Pickering H, Cheetham A, Sata E, Zerihun M, Williams CA, Breuer J, Nute AW, Haile M, Zenu T, Tadesse Z, Bailey RL, Callahan EK, Holland MJ, Nash SD. 2020. Genomics of ocular Chlamydia trachomatis after 5 years of SAFE interventions for trachoma in Amhara, Ethiopia. Journal Infect Dis jiaa615. https://doi.org/10.1093/infdis/jiaa615.

Dirks JAMC, van Liere GAFS, Hobee CIPA, Wolffs P, Dukers-Muijers NHTM. 2019. Genital and anal Chlamydia trachomatis bacterial load in concurrently infected women: a cross-sectional study. Sex Transm Infect 95:317–321. https://doi.org/10.1136/sextrans-2018-053678.

Dubbink JH, de Waaij DJ, Bos M, van der Eem L, Bébère C, Mbabambaza N, Ouburg S, Peters RPH, Morré SA. 2016. Microbiological characteristics of Chlamydia trachomatis and Neisseria gonorrhoeae infections in South African women. J Clin Microbiol 54:200–203. https://doi.org/10.1128/JCM.02848-15.

Dirks JAMC, Hobee CIPA, van Liere GAFS, Dukers-Muijers NHTM, Wolffs PF, van Boeckel MP. Standardization in quantification of Chlamydia trachomatis bacterial load determination by quantitative PCR: a review of literature and retrospective study. Sex Transm Infect 95:562–566. https://doi.org/10.1136/sextrans-2018-053522.

Dukers-Muijers NH, Speksnijder AG, Morré SA, Wolffs PF, van der Sande MA, Brink AA, van den Broek IV, Werner MI, Hobee CJ. 2013. Detection of anorectal and cervicovaginal Chlamydia trachomatis infections following azithromycin treatment: prospective cohort study with multiple time-sequence measurements of rRNA, DNA, quantitative load and symptoms. PLoS One 8:e81236. https://doi.org/10.1371/journal.pone.0081236.

Kong FY, Hocking JS. 2015. Treatment challenges for urogenital and anorectal Chlamydia trachomatis. BMC Infect Dis 15:293. https://doi.org/10.1186/s12879-015-0103-9.

Chen CY, Chi KH, Alexander S, Isaac CA, Ballard RC. 2008. A real-time quadruple PCR assay for the diagnosis of rectal lymphogranuloma venereum and non-lymphogranuloma venereum Chlamydia trachomatis infections. Sex Transm Infect 84:273–276. https://doi.org/10.1136/sti.2007.029058.

Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peraleta L, Forney LJ. 2011. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 108:4680–4685. https://doi.org/10.1073/pnas.1013898108.

Sharma M, Recuero-Checka MA, Fan FY, Dean D. 2018. Chlamydia trachomatis regulates growth and development in response to host cell fatty acid availability in the absence of lipid droplets. Cell Microbiol 20:cmi.12801. https://doi.org/10.1111/cmi.12801.

Batteiger BE, Wan R, Williams JA, He L, Ma A, Fortenberry JD, Dean D. 2014. Novel Chlamydia trachomatis strains in heterosexual sex partners, Indianapolis, Indiana, USA. Emerg Infect Dis 20:1841–1847. https://doi.org/10.3201/eid2014.130609.

Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772–780. https://doi.org/10.1093/molbev/msm010.

Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9:357–359. https://doi.org/10.1038/nmeth.1923.

Sachidanandam R, Weissman S, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimer BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwook PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Altshuler D, International SNP Map Working Group. 2001. A map of human genome variation from population-scale sequencing. Nature 409:860–866. https://doi.org/10.1038/35037112.

Christiansen MT, Brown AC, Yassine M, Meehan C, Schembri WA. 2018. Ultra-fast taxonomic classification of metagenomic data sets. Nucleic Acids Res 45:3849–3859. https://doi.org/10.1093/nar/gky764.

Mtinu P, Ndoni M, Aigbavboa CO, Kandungu M, Mung corporate. 2019. A robust and cost-effective method for Chlamydia trachomatis detection in urogenital specimens from patients attending antenatal care: a prospective cohort study. PLoS One 14:e0213112. https://doi.org/10.1371/journal.pone.0213112.

Bowden et al.

March/April 2021 Volume 6 Issue 2 e01302-20

mSphere.asm.org
taxonomic profiling. Nat Methods 12:902–903. https://doi.org/10.1038/nmeth.3589.
72. Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26:841–842. https://doi.org/10.1093/bioinformatics/btq033.
73. Li H. 2013. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv.
74. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078–2079. https://doi.org/10.1093/bioinformatics/btp352.
75. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb.2012.0021.
76. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. J Mol Biol 215:403–410. https://doi.org/10.1016/S0022-2836(05)80360-2.
77. Garrison E, Marth G. 2012. Haplotype-based variant detection from short-read sequencing. arXiv.
78. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, Parkhill J, Harris SR. 2015. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids Res 43:e15. https://doi.org/10.1093/nar/gku1196.
79. Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogeny. Bioinformatics 30:1312–1313. https://doi.org/10.1093/bioinformatics/btu033.
Supplemental Material

- **FIG S1**

Coverage plots for reference strain D/UW-3/Cx. All the rRNA genes were masked before mapping the reads in order to avoid nonspecific read mapping of the reads because of the usage of RNA bait capture technology for enrichment and direct sequencing. The two distinct gaps seen are the two repeated 23S rRNA genes, and that gap is visible because the lengths of the 23S RNA genes are greater than those of 5S and 16S rRNAs. Download **FIG S1, PDF file, 0.2 MB**.

This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

- **FIG S2**

Coverage plots for Lb strain and patient specimen sets. All the rRNA genes were masked before mapping the reads in order to avoid nonspecific read mapping of the reads because of the usage of RNA bait capture technology for enrichment and direct sequencing. The two distinct gaps seen are the two repeated 23S rRNA genes, and that gap is visible because the lengths of the 23S RNA genes are higher than those of 5S and 16S rRNAs. Download **FIG S2, PDF file, 0.2 MB**.

This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.
**Supplementary Table 1**: Primers used for PCR amplification and sequencing of the entire *C. trachomatis* plasmid for each patient sample set.

| Fragment | PCR primer   | PCR primer sequence (5’-3’) | Fragment size (bp) | Sequencing primer | Sequencing primer sequence (5’-3’) |
|----------|--------------|-----------------------------|--------------------|-------------------|-----------------------------------|
| Fragment 1 | F1_Foward    | AACTCTTGTTGTAGACTTTGCA      | 1751               | F1_Reverse_seq1   | TGACTTGTTGTACAGGAATCCCT           |
|          | F1_Reverse   | AACAAGTTCGAGCAGCAAGC        |                    | Same as F1_Reverse |                                   |
| Fragment 2 | F2_Foward    | GCTTGCTGCTCGAACCTTGTT      | 1750               | Same as F2_Foward |                                   |
|          | F2_Reverse   | TGTAATACCGAAGAAGAACCGA      |                    | Same as F2_Reverse |                                   |
| Fragment 3 | F3_Foward    | CATGGATCGTTTTCTCTTGG        | 1900               | Same as F3_Foward |                                   |
|          | F3_Reverse   | CCCATACCACCCGCTTTCT         |                    | Same as F3_Reverse |                                   |
| Fragment 4 | F4_Foward    | CGTATTCATTACGTGAGCCCG       | 1474               | Same as F4_Foward |                                   |
|          | F4_Reverse   | TCGATCCAAACTCTGACTTCTC      |                    | Same as F4_Reverse |                                   |
| Fragment 5 | F5_Foward    | ACTCTCAGAGGAAAACGTGA        | 828                | Same as F5_Foward |                                   |
|          | F5_Reverse   | TCTCTCTCGTAAATCAAATCCCT     |                    | Same as F5_Reverse |                                   |
**Supplementary Table 2:** List of *Chlamydia trachomatis* genomes and their NCBI/SRA accession IDs used for reconstructing the global phylogenetic tree and subsequent putative recombination detection analysis

| Sample Id   | omp A genotype | NCBI/SRA Accession Ids |
|-------------|----------------|------------------------|
| Ja_107R     | Ja             | PRJNA609714            |
| Ja_107V     | Ja             | PRJNA609714            |
| Ja_192R     | Ja             | PRJNA609714            |
| Ja_192V     | Ja             | PRJNA609714            |
| G_72R       | G              | PRJNA609714            |
| G_72V       | G              | PRJNA609714            |
| G_98R       | G              | PRJNA609714            |
| G_98V       | G              | PRJNA609714            |
| A_2497      | A              | nc_017437.1            |
| A_2497_1    | A              | nc_016798.1            |
| A_363       | A              | nc_020966.1            |
| A_5291      | A              | nc_020939.1            |
| A_7249      | A              | nc_020944.1            |
| A_HAR13     | A              | nc_007429.1            |
| B_Jali20    | B              | nc_012686.1            |
| B_TZ1A828   | B              | nc_012687.1            |
| C_TW3       | C              | nc_023060.1            |
| chxRP1H1    | D              | nz_cp020537.1          |
| chxRP4D10   | D              | nz_cp020536.1          |
| chxRP4F1    | D              | nz_cp020535.1          |
| D_13-96     | Da             | nc_022119.1            |
| D_2923      | Da             | ACFJ01000001          |
| D_2s        | D              | SRA051544.1            |
| D_43n1      | D              | SRA051526.1            |
| D_84s       | D              | SRA051539.1            |
| D_CS637_11  | D              | nz_cp007131.1          |
| D_SotonD5   | D              | nc_020943.1            |
| D_UW3       | D              | AE001273               |
| D_EC        | D              | nc_017434.1            |
| D_LC        | D              | nc_017436.1            |
| E_11023     | E              | nc_017431.1            |
| E_150       | E              | nc_017439.1            |
| E_5s        | E              | SRA051547.1            |
| E_Bour      | E              | nc_020971.1            |
| E_CS1025_11 | E              | nz_cp010567.1          |
| E_DK20      | E              | nz_cp015304.1          |
| E_IU824     | E              | nc_020511.1            |
| E_IU888     | E              | nc_020512.1            |
| E_SotonE4   | E              | nc_020969.1            |
| E_SW3       | E              | nc_017952.1            |
| E-103       | E              | nz_cp015294.1          |
| E-160       | E              | nz_cp015296.1          |
| E-32931     | E              | nz_cp015302.1          |
| E-547       | E              | nz_cp015298.1          |
| E-8873      | E              | nz_cp015300.1          |
| Sequence | Species | Code   | Description |
|----------|---------|--------|-------------|
| SQ14     | Ia      | nz_cp017739.1 |             |
| SQ15     | K       | nz_cp017745.1 |             |
| SQ19     | K       | nz_cp017746.1 |             |
| SQ20     | H       | nz_cp017732.1 |             |
| SQ24     | H       | nz_cp017733.1 |             |
| SQ25     | Ja      | nz_cp017743.1 |             |
| SQ29     | Da      | nz_cp017731.1 |             |
| SQ32     | Da      | nz_cp017730.1 |             |
| Sweden2  | E       | nc_017441.1   |             |
Table S3. Genes present in putative recombination blocks for patient specimen sets.

| Lineages/Clinical sample | Total # of SNPs outside putative recombinant sites | Total # of SNPs inside putative recombinant sites | r/m | rho/theta | Putative Recombinant sites | Start genomic coordinates | End genomic coordinates | homoplasy snps within the putative recombinant sites |
|--------------------------|----------------------------------------------------|--------------------------------------------------|-----|-----------|----------------------------|---------------------------|-------------------------|-----------------------------------------------|
| Prevalent - 192R-192V    | 419                                                | 139                                              | 3.014 | 0.0431     | Block 1                    | 90931                     | 98123                   | 21                             |
|                          |                                                    |                                                  |      |            | Block 2                    | 313243                    | 366721                  | 222                            |
|                          |                                                    |                                                  |      |            | Block 3                    | 404379                    | 407297                  | 13                             |
|                          |                                                    |                                                  |      |            | Block 4                    | 439342                    | 446179                  | 16                             |
|                          |                                                    |                                                  |      |            | Block 5                    | 755205                    | 756077                  | 11                             |
|                          |                                                    |                                                  |      |            | Block 6                    | 768836                    | 781753                  | 136                            |
| Prevalent -107R 107V     | 260                                                | 45                                               | 5.777 | 0.1111     | Block 1                    | 425626                    | 426421                  | 7                              |
|                          |                                                    |                                                  |      |            | Block 2                    | 732506                    | 738362                  | 10                             |
|                          |                                                    |                                                  |      |            | Block 3                    | 754335                    | 756077                  | 14                             |
|                          |                                                    |                                                  |      |            | Block 4                    | 764505                    | 782188                  | 157                            |
|                          |                                                    |                                                  |      |            | Block 5                    | 1018158                   | 1026663                 | 72                             |
| Non-prevalent - 72R 72V  | 213                                                | 56                                               | 3.8035 | 0.05357    | Block 1                    | 790402                    | 811640                  | 95                             |
|                          |                                                    |                                                  |      |            | Block 2                    | 818795                    | 820024                  | 7                              |
|                          |                                                    |                                                  |      |            | Block 3                    | 825543                    | 853694                  | 111                            |
| Non-prevalent - 98V 98R  | 21                                                 | 32                                               | 0.6562 | 0.0312     | Block 1                    | 120752                    | 135523                  | 21                             |
Genes present within the predicted putative recombinant sites

smpB (CT_076), Thiamine biosynthesis lipoprotein (CT_077), hsdM (CT_078), Hypothetical Protein (CT_079), lnuB (CT_080), hypothetical protein (CT_081), hypothetical protein (CT_082), TNDPase (CT_083), phospholipase (CT_084) and decarboxylase (CT_085)
gcvH (CT_282), hypothetical protein (CT_283), phospholipase D (CT_284), plhA_1 (CT_285), clpC (CT_286), MmuA (CT_287), hypothetical protein (CT_288), hypothetical protein (CT_289), plhN_1 (CT_290), dut (CT_292), accD (CT_293), sodM (CT_294), nusA_1 (CT_295), hypothetical protein (CT_296), def (CT_353), kgsA (CT_354), hypothetical protein (CT_355), yylA (CT_356)

DNA topoisomerase IV subunit A

Type III secretion system protein (CT_672), pkn5 (CT_673), yscC (CT_674), karG (CT_675), protein-arginine kinase activator protein (CT_676), rnf (CT_677), pydH (CT_678), tuf (CT_679), rs2 (CT_680), ompA (CT_681) and pbpB (CT_682)

porin (CT_372), pyruvoyl-dependent arginine decarboxylase (CT_373)

recC (CT_640), yylD (CT_641), hypothetical protein (CT_642), topA (CT_643)

sfbB (CT_650), hypothetical protein (CT_659), DNA topoisomerase IV subunit A (CT_660), hypothetical protein (CT_661), hypothetical protein (CT_662), yscF (CT_663), hypothetical protein (CT_664), hypothetical protein (CT_665), hypothetical protein (CT_666), hypothetical protein (CT_667), Type III secretion system protein (CT_672), pkn5 (CT_673), yscC (CT_674), karG (CT_675), protein-arginine kinase activator protein (CT_676), rnf (CT_677), pydH (CT_678), tuf (CT_679)

xerD (CT_864), hypothetical protein (CT_865), glgB (CT_866), dnaB (CT_867), dnaB (CT_868), dnaN (CT_869), hypothetical protein (CT_870), hypothetical protein (CT_871), yscN (CT_872), hypothetical protein (CT_873), hypothetical protein (CT_874), hypothetical protein (CT_875), hypothetical protein (CT_876), hypothetical protein (CT_877), hypothetical protein (CT_878), hypothetical protein (CT_879), hypothetical protein (CT_880), hypothetical protein (CT_881), hypothetical protein (CT_882), hypothetical protein (CT_883), hypothetical protein (CT_884), hypothetical protein (CT_885)

inclusion membrane protein D (CT_115)
in (CT_300), pknD (CT_301), valS (CT_302), hypothetical protein (CT_303), alpK (CT_304), alpI (CT_305), alpD (CT_306), alpB (CT_307), alpA (CT_308), hypothetical protein (CT_309), alpE (CT_310), hypothetical protein (CT_311), hypothetical protein (CT_312), Lal (CT_313), GTPase Der (CT_314), pmlB_2 (CT_315), dppX (CT_305)

3), cell division protein (CT_326), mra (CT_327), hypothetical protein (CT_728), secS (CT_729), ribD (CT_730), ribA/ribB (CT_731), ribE (CT_732), hypothetical protein (CT_733), lipoprotein (CT_734), dagA_2 (CT_735), hypothetical protein (CT_736), hypothetical protein (CT_737), yycJ (CT_738), ftsK (CT_739),
gcsH (CT_282), hypothetical protein (CT_283), phospholipase D (CT_284), lplA_1 (CT_285), clpC (CT_286), MnmA (CT_287), hypothetical protein (CT_288), hypothetical protein (CT_289), plsN_1 (CT_290), dut (CT_292), accD (CT_293), sodM (CT_294), mrsA_1 (CT_295), hypothetical protein (CT_296), rnc (CT_297), radA (CT_298), hemC (CT_299), hypothetical protein (CT_300), pknD (CT_301), infA (CT_302), infA (CT_303), hypothetical protein (CT_324), SufE (CT_325), hypothetical protein (CT_326), trpC (CT_327).

rpoC (CT_314), rpoB (CT_315), d7 (CT_316), d10 (CT_317), d11 (CT_318), ausG (CT_320), secE (CT_321), infA (CT_322), infA (CT_323), hypothetical protein (CT_324), SufE (CT_325), hypothetical protein (CT_326), trpC (CT_327).

yycf (CT_738), fosK (CT_739).